Clinical Trials
New medicines would not be possible without patient participation in clinical trials; we are grateful to all those who make progress possible.
New medicines would not be possible without patient participation in clinical trials; we are grateful to all those who make progress possible.
At KalVista, we are focused on developing new oral treatments for HAE. Learn more about our clinical studies.
The KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
The KONFIDENT Study (KVD900-301) was a Phase 3 clinical trial of sebetralstat for the oral, on-demand treatment of hereditary angioedema (HAE) attacks. The KONFIDENT Study is completed, and positive topline Phase 3 data results were reported in February 2024.
